Trial Profile
A study analysing neutrophil-to-lymphocyte ratio as a prognostic marker in head and neck squamous cell cancer patients treated with platinum based chemptherapy and cetuximab in first line setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Dec 2016
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Paclitaxel
- Indications Head and neck cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 06 Dec 2016 New trial record
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress